本文選題：子宮內(nèi)膜腺癌 + 免疫組織化學(xué)��； 參考：《川北醫(yī)學(xué)院》2015年碩士論文

【摘要】：目的:通過檢測跨膜蛋白CD151在60例子宮內(nèi)膜腺癌和42例正常子宮內(nèi)膜組織中的表達(dá)水平,以及CD151在不同分期、不同分化程度的癌組織的表達(dá)差異,探討其臨床意義。方法:采用免疫組化S-P法檢測CD151在60例子宮內(nèi)膜腺癌以及42例正常子宮內(nèi)膜組織的表達(dá)水平,通過雙評半定量法進(jìn)行評分,積分≥2分為陽性,2分為陰性。采用單因素方差分析、卡方檢驗(yàn),分析CD151在子宮內(nèi)膜腺癌組織與正常子宮內(nèi)膜組織,癌癥組織不同分期、不同分化程度、不同年齡組間表達(dá)水平的差異性。結(jié)果:CD151在60例子宮內(nèi)膜腺癌的陽性表達(dá)率為71.7%(43/60),42例正常子宮內(nèi)膜組織表達(dá)率為35.7%(15/42),兩組間比較P=0.0001,差異有統(tǒng)計(jì)學(xué)意義;不同臨床病理分期的子宮內(nèi)膜癌組織中CD151陽性表達(dá)如下:I期為39.1%(9/23),II期為66.7%(14/21),Ⅲ期為81.3%(13/16),兩兩間比較P=0.023,差異有統(tǒng)計(jì)學(xué)意義;CD151在子宮內(nèi)膜癌不同組織分化程度中陽性表達(dá)如下:G1:40.9%(9/22),G2:58.8%(10/17),G3:81.0%(17/21),兩兩間比較P=0.027,差異有統(tǒng)計(jì)學(xué)意義;不同年齡組內(nèi)膜腺癌組織表達(dá)情況:≥50歲組為75.0%(39/52),50歲組為62.5%(5/8),組間比較P=0.429,差異無統(tǒng)計(jì)學(xué)意義。結(jié)論:通過數(shù)據(jù)分析顯示CD151在子宮內(nèi)膜腺癌較正常子宮內(nèi)膜組織表達(dá)明顯上調(diào),提示CD151可能參與子宮內(nèi)膜癌的發(fā)生,據(jù)此推測其可能對子宮內(nèi)膜癌的分子生物水平機(jī)制研究具有重要意義;通過對CD151在不同臨床病理分期、不同組織分化程度的癌組織中的表達(dá)水平分析,發(fā)現(xiàn)CD151的表達(dá)水平可能作為一個(gè)判斷子宮內(nèi)膜腺癌患者預(yù)后的分子指標(biāo)、指導(dǎo)臨床選擇治療措施。
[Abstract]:Objective: To investigate the expression of transmembrane protein CD151 in 60 cases of endometrial adenocarcinoma and 42 normal endometrium, and the difference in the expression of CD151 in different stages and differentiation, and to explore its clinical significance. Methods: the immunohistochemical S-P method was used to detect the CD151 in 60 cases of endometrial adenocarcinoma and 42 normal uterus. The expression level of intima tissue was scored by a double rating semi quantitative method. The scores were more than 2 points positive and 2 were negative. Single factor analysis of variance and chi square test were used to analyze the difference of CD151 in endometrial adenocarcinoma tissue and normal endometrium, different stages of cancer tissue, different degree of differentiation, and the difference of expression level between different age groups. Results: the positive expression rate of CD151 in 60 cases of endometrial adenocarcinoma was 71.7% (43/60), the expression rate of normal endometrium in 42 cases was 35.7% (15/42), and the difference was statistically significant between the two groups. The positive forms of CD151 in endometrial carcinoma tissues of different clinical and pathological stages were as follows: I phase was 39.1% (9/23), II period 66.7% (14/21), and stage III of 81. were 81.. 3% (13/16), 22 compared with P=0.023, the difference was statistically significant. The positive expression of CD151 in the differentiation degree of endometrial carcinoma was as follows: G1:40.9% (9/22), G2:58.8% (10/17), G3:81.0% (17/21), 22 comparison P=0.027, the difference was statistically significant; the expression of endometrial adenocarcinoma in different age groups was 75% (39/52) in 50 years old group (39/52), 50 The age group was 62.5% (5/8), and the difference was not statistically significant between the groups. Conclusion: data analysis showed that the expression of CD151 in endometrial adenocarcinoma was significantly up-regulated than normal endometrium, suggesting that CD151 might be involved in the occurrence of endometrial carcinoma, so it might be possible to study the molecular biological level mechanism of endometrial carcinoma. By analyzing the expression level of CD151 in different clinical pathological stages and differentiation of different tissues, it is found that the expression level of CD151 may be a molecular marker to judge the prognosis of endometrial adenocarcinoma and guide the clinical selection.

【學(xué)位授予單位】：川北醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 趙冬梅;佟麗波;盧北燕;趙春紅;尹興忠;劉裴麗;;Bcl-2和Cox-2在子宮內(nèi)膜癌中的表達(dá)[J];黑龍江醫(yī)藥科學(xué);2009年05期

2 岳曉靜;牛子儒;劉忠宇;侯彩英;姚元慶;;腹腔鏡早期子宮內(nèi)膜癌手術(shù)臨床療效分析[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2013年13期

3 譚春燕;;KAI1蛋白在子宮內(nèi)膜癌中的表達(dá)及其意義[J];中國實(shí)用醫(yī)藥;2008年18期

4 齊艷麗;朱大勇;姜麗紅;;p53、p21及ER、PR在子宮內(nèi)膜癌中的表達(dá)及意義[J];中國實(shí)用醫(yī)藥;2010年26期

5 張愛榮,孫樹三,張振國,孔北華;子宮內(nèi)膜癌組織中Bcl-2蛋白表達(dá)的免疫組化測定及其臨床意義的研究[J];現(xiàn)代婦產(chǎn)科進(jìn)展;1999年01期

，

本文編號：1782089